Despite the recent regulations to improve price transparency in healthcare and coverage, most Americans are still not shopping around for better prices.
There is nothing inherently wrong with profiting from old drugs. It depends on the drug in question, its efficacy and safety, and the context within which it was approved and priced in the market. Problems can arise if the newly branded drug has limite…
It’s been nearly two months since Novavax submitted a emergency use authorization (EUA) application to the U.S. Food and Drug Administration (FDA) for Nuvaxovid to be used as a booster.
The experience of our peers across the pond shows that the United States should promote choice and competition in our own healthcare system—not move to a single-payer system where government is the sole insurance provider.
Amazon, CVS and Walmart have big healthcare ambitions. But critics say the healthcare system is far too complex for these retailers to figure out. How will this high-stakes game end?